Biopharmaceutical company Amgen (NASDAQ:AMGN) on Tuesday reported positive Phase 2 data at 52 weeks for MariTide, an investigational treatment for obesity.

The drug demonstrated significant weight loss in study participants with and without Type 2 diabetes.

In people with obesity or overweight, MariTide was associated with up to 20% weight loss without a plateau, indicating the potential for further weight loss beyond 52 weeks. In those with Type 2 diabetes up to 17% weight loss was achieved, also without a weight loss plateau, and with lowered average haemoglobin A1C (HbA1c) levels.

The drug also improved various cardiometabolic parameters, including blood pressure and triglyceride levels. Amgen plans to initiate a Phase 3 clinical development programme, MARITIME, to further evaluate MariTide's efficacy and safety.